New Guidance, New Data and New Targets for the Management of Hyperlipidemia
EP. 1: LDL-C and Cardiovascular Disease Risk
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.
EP. 2: New Guidance in Lowering LDL-C
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.
EP. 3: Real-World Data on Achieving LDL Thresholds
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.
EP. 4: Real-World Outcomes Data on Failure to Achieve LDL-C Thresholds
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.
EP. 5: Reasons for Not Reaching Thresholds
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC The reasons many patients do not reach LDL-cholesterol thresholds.
EP. 6: LDL Cholesterol as a Performance Measure
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.
EP. 7: Disparities in Managing Patients
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.
EP. 8: Statin Intolerance
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.
EP. 9: Nonstatin Lipid-Lowering Agents
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.
EP. 10: Starting Combination Therapy Early
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.
EP. 11: Long-term efficacy and safety of PCSK9 inhibitors
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.
EP. 12: The Role of Lipoprotein A in Lipid Lowering
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.
EP. 13: Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.
EP. 14: Clinical Pearls on Lipid Management
ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.
